Skip to content

Research at St Andrews

Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer’s disease treatment

Research output: Contribution to journalLetter

Author(s)

Lukas Hroch, Ondrej Benek, Patrick Guest, Laura Aitken, Ondrej Soukup, Jana Janockova, Karel Musil, Vlastimil Dohnal, Rafael Dolezal, Kamil Kuca, Terry K Smith, Frank J Gunn-Moore, K Musilek

School/Research organisations

Abstract

Amyloid-beta peptide (Aβ) has been recognized to interact with numerous proteins, which may lead to pathological changes in cell metabolism of Alzheimer’s disease (AD) patients. One such known metabolic enzyme is mitochondrial amyloid-binding alcohol dehydrogenase (ABAD), also known as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10). Altered enzyme function caused by the Aβ-ABAD interaction, was previously shown to cause mitochondrial distress and a consequent cytotoxic effect, therefore providing a feasible target in AD drug development. Based on previous frentizole derivatives studies, we report two novel series of benzothiazolyl ureas along with novel insights into the structure and activity relationships for inhibition of ABAD. Two compounds (37, 39) were identified as potent ABAD inhibitors, where compound 39 exhibited comparable cytotoxicity with the frentizole standard; however, one-fold higher cytotoxicity than the parent riluzole standard. The calculated and experimental physical chemical properties of the most potent compounds showed promising features for blood-brain barrier penetration.
Close

Details

Original languageEnglish
Pages (from-to)3675-3678
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume26
Issue number15
Early online date30 May 2016
DOIs
Publication statusPublished - 1 Aug 2016

    Research areas

  • Alzheimer's disease (AD), Amyloid-beta peptide (Aβ), Mitochondria, Amyloid binding alcohol dehydrogenase (ABAD), 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), Benzothiazole, Riluzole

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Novel benzothiazole-based ureas as 17β-HSD10 inhibitors, a potential Alzheimer’s disease treatment

    Aitken, L., Benek, O., McKelvie, B., Hughes, R. E., Hroch, L., Schmidt, M., Major, L. L., Vinklarova, L., Kuca, K., Smith, T. K., Musilek, K. & Gunn-Moore, F. J., 29 Jul 2019, In : Molecules. 24, 15, 2757.

    Research output: Contribution to journalArticle

  2. In vitro assay development and HTS of small molecule human ABAD/17β-HSD10 inhibitors as therapeutics in Alzheimer’s Disease

    Aitken, L., Baillie, G., Pannifer, A., Morrison, A., Jones, P. S., Smith, T. K., McElroy, S. P. & Gunn-Moore, F. J., Jul 2017, In : SLAS Discovery. 22, 6, p. 676-685 11 p.

    Research output: Contribution to journalArticle

  3. 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: design, synthesis and in vitro evaluation

    Benek, O., Hroch, L., Aitken, L., Dolezal, R., Guest, P., Benkova, M., Soukup, O., Musil, K., Hughes, R., Kuca, K., Smith, T. K., Gunn-Moore, F. & Musilek, K., Jun 2017, In : Medicinal Chemistry. 13, 4, p. 345-358 14 p.

    Research output: Contribution to journalArticle

  4. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s disease treatment

    Hroch, L., Guest, P., Benek, O., Soukup, O., Janockova, J., Dolezal, R., Kuca, K., Aitken, L., Smith, T. K., Gunn-Moore, F., Zala, D., Ramsay, R. R. & Musilek, K., 1 Feb 2017, In : Bioorganic & Medicinal Chemistry. 25, 3, p. 1143-1152 10 p.

    Research output: Contribution to journalArticle

  5. 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders

    Benek, O., Hroch, L., Aitken, L., Gunn-Moore, F., Vinklarova, L., Kuca, K., Perez, D. I., Perez, C., Martinez, A., Fisar, Z. & Musilek, K., 2018, In : Journal of Enzyme Inhibition and Medicinal Chemistry. 33, 1, p. 665-670 6 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Bioorganic and Medicinal Chemistry Letters (Journal)

    Stuart John Conway (Editor)
    2006 → …

    Activity: Publication peer-review and editorial work typesEditor of research journal

Related by journal

  1. Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines

    Winum, J-Y., Carta, F., Ward, C., Mullen, P., Harrison, D., Langdon, S. P., Cecchi, A., Scozzafava, A., Kunkler, I. & Supuran, C. T., 15 Jul 2012, In : Bioorganic and Medicinal Chemistry Letters. 22, 14, p. 4681-4685 5 p.

    Research output: Contribution to journalArticle

  2. 6 ''-Azido-6 ''-deoxy-UDP-N-acetylglucosamine as a glycosyltransferase substrate

    Mayer, A., Gloster, T. M., Chou, W. K., Vocadlo, D. J. & Tanner, M. E., 15 Feb 2011, In : Bioorganic and Medicinal Chemistry Letters. 21, 4, p. 1199-1201 3 p.

    Research output: Contribution to journalArticle

  3. Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors—implications for early Myasthenia gravis treatment.

    Komloova, M., Musilek, K., Horova, A., Holas, O., Dohnal, V., Gunn-Moore, F. J. & Kuca, K., 2011, In : Bioorganic and Medicinal Chemistry Letters. 21, p. 2505-2509

    Research output: Contribution to journalArticle

  4. First small molecular inhibitors of T. brucei dolicholphosphate mannose synthase (DPMS), a validated drug target in African sleeping sickness

    Smith, T. K., Young, B. L., Denton, H., Hughes, D. L. & Wagner, G. K., 15 Mar 2009, In : Bioorganic and Medicinal Chemistry Letters. 19, 6, p. 1749-1752 4 p.

    Research output: Contribution to journalArticle

ID: 243084363

Top